INBX financials
Inhibrx Biosciences (INBX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
INBX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $1.30M | -$1.18M | -$135.03M | -$140.06M | -9.04 |
| 2024 | $200.00K | -$2.08M | -$331.45M | $1.69B | 116.58 |
| 2023 | $1.80M | $609.00K | -$219.22M | -$241.36M | -5.12 |
| 2022 | $2.19M | -$107.99M | -$129.12M | -$145.23M | -3.62 |
| 2021 | $7.12M | $4.44M | -$76.67M | -$81.77M | -2.15 |
| 2020 | $12.81M | $0.00 | -$67.44M | -$76.12M | 0.00 |
- INBX revenue was $1.30M in fiscal 2025, net income -$140.06M.
Updated 2026-11-07 11:56 UTC